PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT ID: NCT01659970

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line platinum-based chemotherapy. Eligible patients will be followed for 12 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Squamous Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/= 18 years of age
* Histologically or cytologically confirmed advanced (Stage IIIB) or metastatic (Stage IV) squamous non-small cell lung cancer after failure of first-line platinum-based chemotherapy
* Patients for whom the treating physician has decided to initiate treatment with Tarceva

Exclusion Criteria

* Mixed non-small cell and small-cell lung carcinoma or mixed squamous cell carcinoma with predominant adenocarcinoma component
* Current participation in a clinical trial evaluating an anticancer treatment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Abbeville, , France

Site Status

Agen, , France

Site Status

Aix-en-Provence, , France

Site Status

Aix-en-Provence, , France

Site Status

Amiens, , France

Site Status

Angers, , France

Site Status

Antibes, , France

Site Status

Armentières, , France

Site Status

Aulnay-sous-Bois, , France

Site Status

Bar-le-Duc, , France

Site Status

Bayonne, , France

Site Status

Beuvry, , France

Site Status

Bordeaux, , France

Site Status

Boulogne-Billancourt, , France

Site Status

Bourg-en-Bresse, , France

Site Status

Brive-la-Gaillarde, , France

Site Status

Bron, , France

Site Status

Bry-sur-Marne, , France

Site Status

Carcassonne, , France

Site Status

Castres, , France

Site Status

Chalon-sur-Saône, , France

Site Status

Chambéry, , France

Site Status

Charleville-Mézières, , France

Site Status

Chaumont, , France

Site Status

Chauny, , France

Site Status

Clamart, , France

Site Status

Clermont-Ferrand, , France

Site Status

Colmar, , France

Site Status

Compiègne, , France

Site Status

Créteil, , France

Site Status

Dijon, , France

Site Status

Dijon, , France

Site Status

Draguignan, , France

Site Status

Dunkirk, , France

Site Status

Ermont, , France

Site Status

Épernay, , France

Site Status

Férolles-Attilly, , France

Site Status

Forbach, , France

Site Status

Gap, , France

Site Status

Gleizé, , France

Site Status

Gonesse, , France

Site Status

La Rochelle, , France

Site Status

La Source, , France

Site Status

La Tronche, , France

Site Status

Lagny-sur-Marne, , France

Site Status

Le Mans, , France

Site Status

Le Mans, , France

Site Status

Le Puy-en-Velay, , France

Site Status

Lille, , France

Site Status

Lille, , France

Site Status

Lille, , France

Site Status

Limoges, , France

Site Status

Lisieux, , France

Site Status

Longjumeau, , France

Site Status

Lorient, , France

Site Status

Lyon, , France

Site Status

Lyon, , France

Site Status

Manosque, , France

Site Status

Mantes-la-Jolie, , France

Site Status

Mareuil-lès-Meaux, , France

Site Status

Marseille, , France

Site Status

Meaux, , France

Site Status

Metz, , France

Site Status

Metz-Tessy, , France

Site Status

Mont-de-Marsan, , France

Site Status

Montpellier, , France

Site Status

Nancy, , France

Site Status

Nantes, , France

Site Status

Narbonne, , France

Site Status

Neuilly-sur-Seine, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Perpignan, , France

Site Status

Perpignan, , France

Site Status

Pierre-Bénite, , France

Site Status

Poitiers, , France

Site Status

Pontoise, , France

Site Status

Quimper, , France

Site Status

Rambouillet, , France

Site Status

Reims, , France

Site Status

Reims, , France

Site Status

Rennes, , France

Site Status

Rouen, , France

Site Status

Rouen, , France

Site Status

Saint-Dié, , France

Site Status

Saint-Dizier, , France

Site Status

Saint-Jean, , France

Site Status

Saint-Laurent-du-Var, , France

Site Status

Saint-Omer, , France

Site Status

Saint-Priest-en-Jarez, , France

Site Status

Saint-Priest-en-Jarez, , France

Site Status

Saint-Quentin, , France

Site Status

Saintes, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Strasbourg, , France

Site Status

Thionville, , France

Site Status

Thonon-les-Bains, , France

Site Status

Toulon, , France

Site Status

Toulon, , France

Site Status

Toulouse, , France

Site Status

Tours, , France

Site Status

Valence, , France

Site Status

Vandœuvre-lès-Nancy, , France

Site Status

Vannes, , France

Site Status

Verdun, , France

Site Status

Vénissieux, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML28195

Identifier Type: -

Identifier Source: org_study_id